Abstract: A method of treating a subject having or at risk for having an HIV-1 virus infection, by administering to the subject a therapeutically effective amount of a composition comprising a CRISPR-associated endonuclease, and two or more different multiplex guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of proviral DNA of the virus that is unique from the genome of the host cell, cleaving a double strand of the proviral DNA at a first target protospacer sequence with the CRISPR-associated endonuclease, cleaving a double strand of the proviral DNA at a second target protospacer sequence with the CRISPR-associated endonuclease, excising an entire HIV-1 proviral genome, eradicating the HIV-1 proviral DNA from the host cell, and completely resolving the symptoms of HIV-1, decreasing the severity of the symptoms of HIV-1, or slowing HIV-1's progression.
Type:
Application
Filed:
April 2, 2018
Publication date:
August 9, 2018
Applicant:
Temple University of the Commonwea lth System of Higher Education
Abstract: A method of immunizing a subject at risk of HIV-1 virus infection, by administering to the subject a prophylactically effective amount of a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different multiplex guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of proviral DNA of the virus that is unique from the genome of the host cell, cleaving a double strand of the proviral DNA at a first target protospacer sequence with the CRISPR-associated endonuclease, cleaving a double strand of the proviral DNA at a second target protospacer sequence with the CRISPR-associated endonuclease, excising an entire HIV-1 proviral genome, eradicating the HIV-1 proviral DNA from the host cell, and preventing HIV-1 virus infection in the subject.
Type:
Application
Filed:
March 29, 2018
Publication date:
August 2, 2018
Applicant:
Temple University of the Commonwealth System of Higher Education
Abstract: A method of treating a subject having or at risk for having an HIV-1 virus infection, by administering to the subject a therapeutically effective amount of a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different multiplex guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of proviral DNA of the virus that is unique from the genome of the host cell, cleaving a double strand of the proviral DNA at a first target protospacer sequence with the CRISPR-associated endonuclease, cleaving a double strand of the proviral DNA at a second target protospacer sequence with the CRISPR-associated endonuclease, excising an entire HIV-1 proviral genome, eradicating the HIV-1 proviral DNA from the host cell, and causing neither genotoxicity nor off-target editing to the host.
Type:
Application
Filed:
March 15, 2018
Publication date:
July 26, 2018
Applicant:
Temple University of the Commonwealth System of Higher Education
Abstract: Synergistic pharmaceutical compositions including an RNase P inhibitor and a tRNA synthetase inhibitor are provided, as well as methods for their use in treating infections. Also provided herein are methods of using the compositions to inhibit a bacterial tRNA synthetase in a cell and to decolonize bacteria on a surface.
Type:
Grant
Filed:
October 30, 2015
Date of Patent:
July 24, 2018
Assignees:
University of Rochester, Temple University—Of the Commonwealth System of Higher Education
Abstract: A method of treating a subject having or at risk for having a virus infection, by administering a therapeutically effective amount of a composition comprising a vector encoding a CRISPR-associated endonuclease and at least two guide RNAs that are complementary to two target sequences spanning from the 5?- to 3?-LTRs of the sequence in the virus, and completely excising a fragment of greater than 9000-bp of integrated proviral DNA that spanned from its 5?- to 3?-LTRs. A method of treating a subject having or at risk for having a genetic caused disease, by administering a therapeutically effective amount of a composition comprising a vector encoding a CRISPR-associated endonuclease and at least two guide RNAs that are complementary to two target sequences spanning from the sequence of the subjects DNA greater than 9000-bp that is chromosomally integrated and causes the genetic caused disease, and excising the chromosomally integrated sequence.
Type:
Application
Filed:
February 22, 2018
Publication date:
July 19, 2018
Applicant:
Temple University of the Commonwealth System of Higher Education
Abstract: The present invention includes a robotic system for the enhanced automation, manipulation, and control of electroprocessing in two or three dimensions. In one embodiment, the system includes a sealed chamber devoid of any electrical or conductive components which would interfere with the electrical field and eventual material fabrication, while still allowing for two-dimensional and three-dimensional robot motion. In certain embodiments, the system of the invention produces materials or scaffolds with complex shapes, including materials with ridges, valleys, curves, and the like, which are difficult or impossible to construct using traditional systems.
Type:
Grant
Filed:
August 22, 2014
Date of Patent:
June 26, 2018
Assignee:
Temple University—Of The Commonwealth System of Higher Education
Inventors:
Jonathan A. Gerstenhaber, Peter I. Lelkes, Yah-el Har-el
Abstract: A method of treating a subject having or at risk for having a virus infection, by administering to the subject a therapeutically effective amount of a composition comprising a vector encoding a CRISPR-associated endonuclease and at least two guide RNAs, wherein the guide RNAs are complementary to two target sequences spanning from the 5?- to 3?-LTRs of the sequence in the virus, and completely resolving the symptoms of a disease, decreasing the severity of the symptoms of the disease, or slowing the disease's progression.
Type:
Application
Filed:
January 31, 2018
Publication date:
June 21, 2018
Applicant:
Temple University of the Commonwealth system of Higher Educaotion
Abstract: A method of treating a subject having a retroviral infection, by administering to the subject a therapeutically effective amount of a composition comprising a vector encoding a CRISPR-associated endonuclease and at least two guide RNAs, wherein the guide RNAs are complementary to two target sequences spanning from the 5?- to 3?-LTRs of the sequence in the retrovirus, and eradicating the retroviral infection. A method of immunizing a subject at risk of retroviral infection, by administering a prophylactically effective amount of a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of proviral DNA of a retrovirus to the subject, and preventing retroviral infection in the subject.
Type:
Application
Filed:
January 31, 2018
Publication date:
June 21, 2018
Applicant:
Temple University of the Commonwealth system of Higher Education
Abstract: Methods of inactivating a proviral DNA genome or a DNA genome integrated into the genome of a host cell latently infected with a retrovirus, by treating the host cell with a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different multiplex guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of the proviral DNA that is unique from the genome of the host cell, cleaving a double strand of the proviral DNA at a first target protospacer sequence with the CRISPR-associated endonuclease, cleaving a double strand of the proviral DNA at a second target protospacer sequence with the CRISPR-associated endonuclease, excising an entire proviral genome of the proviral DNA, and eradicating the proviral DNA from the host cell.
Type:
Application
Filed:
January 25, 2018
Publication date:
June 21, 2018
Applicant:
Temple University of the Commonwealth System of Higher Education
Abstract: Provided is a method for detecting injury to the brain comprising: a) determining the level of a tight junction (TJ) protein in exosomes isolated from a test sample from a subject, wherein the TJ protein is occludin, claudin-3, claudin-5, claudin-12, ZO-1, ZO-2, ZO-3, JAM-A, JAM-B or JAM-C, or any combination thereof; b) comparing the level of the TJ protein in the test sample to the level of the TJ protein in a control sample, wherein an elevated level of the TJ protein in the test sample relative to the level of the TJ protein in the control sample indicates that the subject has an injury to the brain.
Type:
Grant
Filed:
June 25, 2013
Date of Patent:
June 5, 2018
Assignee:
Temple University—Of The Commonwealth System of Higher Education
Inventors:
Servio H. Ramirez, Slava Rom, Yuri Persidsky
Abstract: A method of inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus by treating the host cell with a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) in the proviral DNA, and inactivating the proviral DNA. A composition for use in inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus including isolated nucleic acid sequences comprising a CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a human immunodeficiency virus.
Type:
Grant
Filed:
May 6, 2016
Date of Patent:
May 29, 2018
Assignee:
Temple University of the Commonwealth System of Higher Education
Abstract: A method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy. A pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector. Pharmaceutical compositions including at least one isolated nucleic acid sequence encoding at least one TALEN, at least one ZFN, and gene editing composition of C2c1, C2c3, TevCas9, Archaea Cas9, CasY.1-CasY.
Type:
Application
Filed:
January 8, 2018
Publication date:
May 24, 2018
Applicants:
Excision BioTherapeutics, Inc., Temple University of the Commonwealth System of Higher Education
Inventors:
Kamel Khalili, Thomas Malcolm, Kenneth I. Kohn
Abstract: Pharmaceutical compositions of the invention comprise compounds, compositions, methods useful for the treatment of drug addiction, drug withdrawal, and diseases or conditions that involve dysregulation of glutamate homeostasis in it etiology.
Type:
Grant
Filed:
June 4, 2014
Date of Patent:
May 22, 2018
Assignee:
Temple University of the Commonwealth System of Higher Education
Inventors:
Magid Abou-Gharbia, Wayne E. Childers, Rogelio L. Martinez, Mercy M. Ramanjulu, Benjamin E. Blass
Abstract: An embodiment of the invention relates to the use of stabilized cancer peptide fragments derived from “redoxin proteins” selected from the group consisting of thioredoxin; peroxiredoxin-1, 2 and 3; glutaredoxin-3; glutathione peroxidase-4; and nucleoredoxins for the diagnosis of cancers, particularly pancreatic cancer. A method for the detection of cancer, severity of cancer, and/or effectiveness of a therapeutic regimen comprises detecting and/or measuring the amount of redoxin peptide fragments present in the biological sample of a subject.
Type:
Grant
Filed:
July 15, 2015
Date of Patent:
February 27, 2018
Assignee:
Temple University of the Commonwealth System of Higher Education
Abstract: The present invention provides an isolated population of bone marrow-derived endothelial progenitor cells (EPCs) and uses thereof for the treatment of vascular diseases.
Type:
Grant
Filed:
February 16, 2016
Date of Patent:
February 27, 2018
Assignee:
Temple University—of the Commonwealth System of Higher Education
Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
Type:
Application
Filed:
September 10, 2015
Publication date:
October 19, 2017
Applicant:
Temple University-Of the Commonwealth System of Higher Education
Inventors:
Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
Abstract: A method is provided for treating a patient in need of therapy for central nervous system inflammation comprising administering to that patient a therapeutically effective amount of a cannabinoid agonist having efficacy at the CB2 receptor but having substantially no efficacy at the CB1 receptor at that amount.
Type:
Grant
Filed:
December 5, 2007
Date of Patent:
September 19, 2017
Assignees:
Virginia Commonwealth University, Organix, Inc., Temple University
Inventors:
Billy R. Martin, Mohamad Imad Damaj, Martin W. Adler, Ronald F. Tuma, Ming Zhang, Anu Mahadevan, Raj K. Razdan
Abstract: The present invention relates to biomimetic scaffolds, methods for making the same, and methods for using the same. The scaffolds comprise a plurality of graded or tapered microchannels that provide spatial control for cell penetration. The scaffolds are useful for regenerating missing interface tissue between two adjacent tissues, or regeneration and integration of two adjacent tissues directly.
Type:
Application
Filed:
July 14, 2015
Publication date:
July 20, 2017
Applicant:
Temple University-Of The Commonwealth System of Higher Education
Inventors:
Maobin Yang, Peter I. Lelkes, Riddhi A. Gangolli, Jonathan A. Gerstenhaber, Sean M. Devlin
Abstract: Small molecule inhibitors of bacterial ribonuclease (e.g., RnpA) and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing microbial infections and inhibiting bacterial ribonuclease. Also described herein are methods of identifying compounds for treating or preventing a microbial infection.
Type:
Grant
Filed:
November 5, 2015
Date of Patent:
July 4, 2017
Assignees:
University of Rochester, Board of Regents of the University of Nebraska, Temple University—Of the Commonwealth System of Higher Education
Inventors:
Paul M. Dunman, Patrick D. Olson, Wayne Childers
Abstract: The present invention relates to systems and methods for regenerating ?-cyclodextrin (?-CD) adsorbent after it has been used in a water decontamination process. The regeneration process of the present invention is based on treating ?-CD with ozone gas, i.e., ozonation. In one embodiment, the regeneration process of the present invention comprises the steps of providing a ?-CD adsorbent that has been used in a water decontamination process and removing at least a portion of the contaminants from the ?-CD adsorbent by contacting the contaminants bound to the ?-CD adsorbent with a gas comprising ozone.
Type:
Grant
Filed:
February 27, 2015
Date of Patent:
June 27, 2017
Assignee:
Temple University—Of The Commonwealth System of Higher Education